Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases... Show more
Biogen Inc. is a Cambridge, Massachusetts-based global biotechnology company focused on discovering, developing, and delivering therapies for neurological and rare diseases. Its commercial portfolio spans multiple sclerosis treatments such as Tysabri and Vumerity, spinal muscular atrophy therapy Spinraza, Alzheimer's disease drug Leqembi (developed with Eisai), and the Friedreich ataxia treatment Skyclarys, alongside Qalsody and Zurzuvae. Through its May 2026 acquisition of Apellis, Biogen added the geographic atrophy treatment Syfovre and the complement inhibitor Empaveli to its portfolio. Investors follow the stock for its pipeline of neurology and immunology readouts, its efforts to transition away from a maturing multiple sclerosis franchise, and its ability to sustain revenue growth through newer products.
Over the last 30 days, Biogen shares advanced from a closing price of $227.07 on September 29, 2026 to approximately $251.59, a gain of roughly +10.8%. The move accelerated in the second half of October, with the stock climbing from about $233 in mid-October toward the mid-$250s after the company's third-quarter earnings release, before settling near the $251 area.
The quarterly picture is even stronger. From a close of $209.23 on July 29, 2026, the stock has risen about 20%, reflecting a sustained upward trend rather than a single-session spike. This multi-month advance is consistent with Biogen's year-to-date gain of roughly 44%, outpacing the broader market as the company's growth portfolio gained commercial traction.
The primary catalyst was Biogen's third-quarter 2026 earnings report on October 28. The company posted revenue of $2.80 billion, up 11% year over year and ahead of consensus estimates of roughly $2.59 billion to $2.64 billion. Adjusted earnings per share of $2.62 exceeded the approximately $2.06 analysts had projected, representing a meaningful positive surprise.
Growth in newer products underpinned the beat. Spinraza revenue rose 23% to $461 million on rapid patient conversion to a high-dose regimen, while Leqembi in-market sales climbed 67% to $202 million and Skyclarys grew 34% to $178 million. Syfovre and Empaveli, acquired from Apellis, contributed a combined $243 million in their first full quarter, and management indicated the pair was tracking toward a roughly $1 billion annualized run rate. Biogen also raised the lower end of its 2026 non-GAAP EPS guidance to $12.20, citing business strength and better-than-expected acquisition integration.
The report was not without offsetting items. A GAAP net loss of $20.6 million reflected about $284 million in acquired in-process R&D charges tied primarily to the RayThera acquisition, and the legacy multiple sclerosis franchise continued to face competitive and formulary pressure. Nevertheless, analyst actions around the quarter leaned constructive, including a Buy rating from Piper Sandler and reiterated coverage from other firms, reinforcing investor sentiment.
Over the trailing quarter, Biogen's advance has been driven by a broader narrative of a return to growth. The May 2026 completion of the Apellis acquisition diversified the revenue base beyond neurology into ophthalmology and nephrology, and integration has proceeded faster than initially anticipated, with management targeting $250 million in run-rate cost synergies by the end of 2027. Strong commercial execution across Spinraza, Leqembi, Skyclarys, and the acquired products has shifted the revenue mix decisively toward the growth portfolio, which now accounts for nearly two-thirds of core pharmaceutical revenue.
Investor enthusiasm has also been supported by a rich late-stage pipeline. Management has guided toward multiple registrational readouts over the coming quarters, including Phase 3 data for litifilimab in systemic lupus erythematosus and later readouts for felzartamab and zorevunersen. This combination of improving commercial momentum and near-term catalysts helped the stock sustain its upward trajectory through the quarter.
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a platform that operates hundreds of bots across thousands of tickers. Rather than displaying every available strategy, the page surfaces only the top-performing and most relevant bots, allowing users to focus on signals that have demonstrated recent strength. These bots vary in strategy, timeframe, and performance metrics, so traders can review approaches that align with their own objectives and risk preferences. For investors seeking a data-driven complement to fundamental research, exploring the Trending AI Robots section can offer additional perspective on current market positioning.
Several factors are likely to shape Biogen's near-term outlook. The December readouts for litifilimab's two Phase 3 systemic lupus erythematosus studies represent a key pipeline catalyst, with subsequent data expected for felzartamab and, later, zorevunersen in Dravet syndrome. On the commercial side, investors will monitor whether Leqembi and the Apellis products sustain their growth trajectories and whether formulary and competitive pressures on the multiple sclerosis franchise stabilize. Execution on cost synergies, debt repayment, and the full-year 2026 guidance range of $12.20 to $13.00 in non-GAAP EPS will also be closely watched, alongside any updates on regulatory timelines and macroeconomic conditions affecting the biotech sector.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BIIB saw its Momentum Indicator move above the 0 level on November 16, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 55 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 64%.
Following a +4.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIIB advanced for three days, in 165 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
The Aroon Indicator entered an Uptrend today. In 124 of 199 cases where BIIB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 62%.
The 10-day RSI Indicator for BIIB moved out of overbought territory on October 28, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 18 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 64%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 58 cases where BIIB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for BIIB turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 43 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIIB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
BIIB broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 8 (best 1 - 100 worst), indicating outstanding price growth. BIIB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.947) is normal, around the industry mean (-1.421). P/E Ratio (43.724) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.357) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (3.189) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 84 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIIB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of therapies for people living with neurological, autoimmune and hematologic disorders
Industry PharmaceuticalsMajor